[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620199":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":62,"collaborators":26,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":26,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":50,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Qlaris Bio, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"QLS-111-FDC ophthalmic solution","EXPERIMENTAL","QLS-111-FDC, PF FDC",[13],"Combination Product: QLS-111-FDC",{"label":15,"type":16,"description":17,"interventionNames":18},"Latanoprost ophthalmic solution","ACTIVE_COMPARATOR","PF latanoprost 0.005%",[19],"Drug: Latanoprost (0.005%)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"COMBINATION_PRODUCT","QLS-111-FDC","QLS-111-FDC, a PF FDC administered by topical ophthalmic (TO) application for 14 days in the evening (QPM) in both eyes (OU).",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Latanoprost (0.005%)","PF latanoprost administered by TO application for 14 days QPM OU.",[15],[33],"latanoprost ophthalmic solution 0.005%, PF",[35],{"name":36,"affiliation":5,"role":37},"Barbara M Wirostko, MD","STUDY_DIRECTOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":26,"email":43},"Lisa Brandano","CONTACT","9789302103","lbrandano@qlaris.bio",{"name":45,"role":41,"phone":26,"phoneExt":26,"email":46},"Lauryl Hargreaves","lhargreaves@qlaris.bio",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":26},"Shettle Eye Research","RECRUITING","Largo","Florida","33773","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-82.78842,27.90979,{"lat":60,"lon":59},{"type":63,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100620199","phase-2-study-of-qls-111-fdc-in-open-angle-glaucoma-or-ocular-hypertension-100620199",false,"NCT07354516","Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","A Masked, Randomized, Prospective Study of QLS-111-FDC in Subjects With Open-Angle Glaucoma or Ocular Hypertension","Firecrest","Inclusion Criteria:\n\n* BCVA 1.0 logMAR or better in each eye (equivalent to 20\u002F200)\n* Diagnosis of mild to moderate OAG or OHT in at least one eye\n* IOP ≥19 mmHg at 08:00 hour (H) at Qualification Visits following a run-in with PF latanoprost\n\nExclusion Criteria:\n\n* History of active ocular disease other than mild to moderate OAG\u002FOHT\n* Prior use of any topical PGA without a clinically meaningful response\n* Noncompliant with current ocular anti-hypertensive medications or unwilling to be compliant throughout the study\n* Use of other topical ocular concomitant medications 30 days prior\n* History of angle closure or a narrow angle, significant ocular trauma, ocular infection, uveitis, intraocular surgery in either eye.\n* Central corneal thickness in either eye \\\u003C470 or \\>630 μm\n* Clinically significant systemic or psychiatric disease, chronic kidney disease, or hypertension, hypotension, or diabetes that is uncontrolled.\n* Participation in any investigational study within 30 days prior to Screening\n* Females who are pregnant, nursing, or not using birth control.","ALL","12 Years",{"count":75,"type":76},60,"ESTIMATED","INTERVENTIONAL",[79,80],"PHASE2","PHASE3","Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free \\[PF\\], fixed-dose combination \\[FDC\\] investigational product (IP) in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).",[83,84],"OAG - Open-Angle Glaucoma","OHT - Ocular Hypertension",[86,87,88],"glaucoma","intraocular pressure (IOP)","eye drops","2026-03-30",{"date":91,"type":92},"2026-04-03","ACTUAL",{"date":94,"type":92},"2026-03-18",{"date":96,"type":76},"2026-07-15",{"name":5,"class":6},1]